Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, DeFilipp Z, El-Jawahri A, McAfee SL, Brunner AM, Amrein PC, Mims AS, Knight LW, Kelley D, Bottoms AS, Perry LH, Wahl JL, Brock J, Breton E, Marchione DM, Ho VT, Chen YB.
Fathi AT, et al. Among authors: amrein pc.
Clin Cancer Res. 2023 Jun 1;29(11):2034-2042. doi: 10.1158/1078-0432.CCR-23-0182.
Clin Cancer Res. 2023.
PMID: 37014667
Clinical Trial.